y p o
play

Y P O Potential clinical applications of TMS in pediatrics C T - PowerPoint PPT Presentation

Y P O Potential clinical applications of TMS in pediatrics C T O N O D E S Aaron Boes, MD, PhD A Sidney R. Baer Clinical Neuroscience Fellow, BIDMC E Pediatric Neurologist, MGH L P Y P O C T O N Disclosure: Off-label uses


  1. Y P O Potential clinical applications of TMS in pediatrics C T O N O D E S Aaron Boes, MD, PhD A Sidney R. Baer Clinical Neuroscience Fellow, BIDMC E Pediatric Neurologist, MGH L P

  2. Y P O C T O N Disclosure: Off-label uses of TMS will be discussed O D E S A E L P

  3. Y P O Topics C T Highlight of a few areas in which TMS may find clinical O applications in the pediatric population in the near future. N - Depression O - Rehabilitation D - Epilepsy - Autism E - ADHD S A - Tourrettes E L P

  4. Y P O C T O Please interrupt, ask questions. N O D E S A E L P

  5. Y P O Challenges and opportunities in pediatrics C T Neurodevelopmental disorders are common. 1 in 6 (Boyle, O 2011) N O D Neuropsychiatric disease = #1 worldwide cause of disability E age 10-24 and overall (Lancet, 2011 & 2013) S Current therapies are inadequate A E L P

  6. Y P O Current knowledge gap in clinical neurology and psychiatry… C T Brain disorders currently conceptualized of in terms of O dysfunctional networks (Bianchi, 2012) N Diagnoses are based on behavior \ subjective symptoms, O not network dysfunction. D Therapy does not target dysfunctional networks. E S A E L P

  7. Y P O Bridging the gap – Diagnosis and therapy targeting C dysfunctional networks T O N O D E S A E L P

  8. Y P O Why Pediatrics – Why now? C T O All neurodevelopmental disorders and almost 2/3 of neuropsychiatric disorders manifest in the pediatric population N (Kessler, 2005) O Prevention or early diagnosis \ intervention leads to better outcomes. D E S Research on adults may not apply to pediatric patients A E L P

  9. Y P O Interventions in younger people = better return on investment C T O N O D E S A E L P Heckman, Science , 2006 .

  10. Y P O C T O Depression N O > D E S A E L P

  11. Y P O • Clinical problem: C T - Pediatric depression is common, 11% (nimh.nih.gov) O - 30% of adolescents have complete remission with therapy N March, 2007; March, 2004, Brent 2008, Walkup 2010 O > D E S A E L P

  12. Y P O • Clinical problem: C T - Pediatric depression is common, 11% (nimh.nih.gov) O - 30% of adolescents have complete remission with therapy N March, 2007; March, 2004, Brent 2008, Walkup 2010 O > D ________________________________ E - rTMS works for adult depression S - Younger age may be a predictor of treatment response A (Gershon, 2003; Janicak, 2002, Avery, 2008) E L P

  13. Y P O Use of TMS in treating pediatric depression C T O N O Cristopher Wall Paul Croakin D E S A E L P

  14. Y P O TMS in depressed adolescents C T O Prospective, open multicenter trial of rTMS N in adolescents that have not responded to O two prior antidepressant agents. Age14 – > D 17. E S A E L P

  15. Y P O TMS in depressed adolescents C T O Results: N 7 of 8 tolerated procedure. O > 1 dropped out after first 5 minutes, scalp D discomfort. E S A E L P

  16. Y P O C T O N O D E S A E L P

  17. Y P Larger trial ongoing O C T O N O D Randomized, double-blinded, sham-controlled trial. E S N = 50, projected completion 12/2016 A Age range 12-21 E L Sites: Rochester MN, Charleston, South Carolina P

  18. Y P O C T O N Rehabilitation O > D E S A E L P

  19. Y P O • Clinical problem: C T - Pediatric stroke and cerebral palsy are relatively common O and rehabilitation often does not restore function N O > D E S A E L Bernadette Gillick, Warren Lo, Adam Kirton, Calgary U. Of Minnesota P Ohio State

  20. Y P O C T O 2008, Lancet Neurology N N = 10, 9-13 yo, 1 Hz contralesional, 100% MT, 1200 pulses, 20 minutes x8 days O D E S A E L P

  21. Y P O Spastic cerebral palsy N = 17, All with CP C T Randomized, sham O controlled N O 6 sham, 6 1 Hz, 5 5 Hz > D 5 sessions; 90% MT E Increased range of S motion for 5 Hz A E L P

  22. Y P O • More to read…. C T O N O > D E S A E L P

  23. Y P O C T O N Epilepsy O > D E S A E L P

  24. Y P O Sample case: C 15 year old boy was getting dressed this T morning when his father heard a loud thud. O A few minutes later the father checked on N him and he was sleepy, confused and had O bit his tongue. The confusion improved over D 20 minutes. He has one similar episode, but E nobody observed either. S A E L P

  25. Y P O Differential diagnosis… C T O - Seizure N -Syncope (fainting) O -School avoidance (geometry exam) D E S A E L P

  26. Y P O EEG: C T O N O D A single routine EEG is only ~66% sensitive. E S A Sleep deprivation, hyperventilation and E strobe light slightly improve sensitivity. L P Image http://www.seattlechildrens.org/kids-health/image/ial/images/884/884_image.gif

  27. Y P O Could TMS increase the sensitivity of EEG, C moving from a passive test to actively T O probing for abnormalities? N O D E S A E L P

  28. Y P O C T O N O D E S A E L P

  29. Y P O Study Design: C T O - Comparing standard EEG to EEG + TMS (single pulse directed at N each electrode site, looking for abnormal discharges). O - 15 controls and 15 patients with focal-onset epilepsy D E S A E L P http://www.neuroconn.de/diagnose_en/

  30. Y P O Study Results: C T O - TMS+EEG had no false positive results in N controls. O - Sensitivity of standard EEG: 80% D - Sensitivity of standard EEG + EEG\TMS: E 100% S A E L P

  31. Y P O Sample case: C 15 year old boy with possible seizure. T O N - EEG: Abnormal O - Which medicine to start? D E S A E L P

  32. Y P O Could motor cortex neurophysiology, as C assessed with TMS, guide medication T O selection? N O D E S A E L P

  33. Y P O TMS neurophysiology measures relate to neurotransmitter C systems (e.g. SICI:GABA A LICI – GABA B ICF – glutamate) T O Seizure medicines work differentially on neurotransmitter N systems O D We’re beginning to understand how specific medicines impact TMS-measured neurophysiology (e.g. Lang, 2013) E ________________ S It is possible we could select medicines to correct specific A abnormalities in an individual patient. E L P

  34. Y P O Sample case: C T O - EEG: Abnormal N - Which medicine to start? O - Now on keppra D E S A E L P

  35. Y P O C After starting our patient on 1 gram of keppra twice T a day the mother asks “how do we know that the O medicine is working?” N O > D E S A E L P

  36. Y P O C After starting our patient on 1 gram of keppra twice T a day the mother asks “how do we know that the O medicine is working?” N O Could TMS measures of motor cortex > D neurophysiology give us a clue as to whether the medication is effective? E S A E L P

  37. Y P O C T O N O D E S A E L P

  38. Y P O Design C T • 99 drug naïve patients about to start a seizure O medicine had TMS-based neurophysiological N testing. O • They had repeat testing 4-16 weeks later. > D • They were followed up one year later. E S A E L P

  39. Y P O Results C T • At one year 69 of 99 were seizure free. O N O > D E S A E L P

  40. Y P Effective treatment associated with rise in motor threshold O C T O N O D E S A E L P

  41. Y P O Conclusion C T Increased motor threshold and increased O intracortical inhibition after starting a seizure N medicine may predict its effectiveness. O > D E S A E L P

  42. Y P O Sample case: C Now, fast forward 2 years. Our patient has T tried multiple medications and seizures O persist. An MRI has revealed a focal cortical N dysplasia that is the source of the seizures. O D E S A E L P

  43. Y P O C T O N O D E S A E L P

  44. Y P O Sample case: C fMRI and TMS mapping reveal the dysplasia T is immediately adjacent to motor cortex O hand and face area. Surgery would risk N causing hemiparesis. O D E S A E L P

  45. Y P O TMS for the treatment of epilepsy C T Focal epilepsy often does not respond to O medication and surgery often is not a viable option N O Low frequency TMS is able to decrease excitability > D of underlying cortex. E S Can 1 Hz rTMS to the seizure focus be used to A treat the epilepsy? E L P

  46. Y P O C T O N O D E S A E L P

  47. Y P O Design C T • 64 patients with medically refractory focal O epilepsy N • Group randomly split into treatment and sham O groups, defined by strength of TMS pulse (90% > D vs. 20% motor threshold) E • Daily TMS x14 days. S • Outcome measures: Seizure frequency + A epileptiform discharges on EEG E L P

  48. Y P O C T O N O D E S A E L P

  49. Y P O Results C T • Significant seizure reduction and improved O interictal EEG pattern in treatment group. N • Only 2 patients in treatment group at medial O temporal lobe epilepsy and they did not respond > D E S A E L P

  50. Y P O What about therapeutic rTMS with deep C seizure foci? T O N O > D E S A E L P

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend